Further Reading

Further Reading

Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting -  click here to view

Attainment of Glycemic Goals in Type 2 Diabetes with Once-, Twice-, or Three-times-daily Dosing with Biphasic Insulin Aspart 70/30 (The 1-2-3 Study) -  click here to view

Biphasic insulin aspart 30 + metformin vs once-daily insulin glargine + glimepiride: a study in people with type 2 diabetes - Click here to view (powerpoint presentation)

ACE/AACE Road Map for the Prevention and Treatment of Type 2 Diabetes - Click here to view

Please Log in
Free registration to access disease diagnosis, patient management, physician tools.

Only registered users have access to this content.

Already Registered?

Email    Password   

Not a member?

Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students. 

Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major theraputic areas, disease management, and clinical tools.

As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!

REGISTER today it only takes a minute! and it's FREE

If you are not a healthcare professional please visit our patient site.

Having problems?

Use our forgotten password facility or email us at: contact@epgonline.org

Exit Log in